Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 25,324,502
  • Shares Outstanding, K 145,719
  • Annual Sales, $ 9,836 M
  • Annual Income, $ 1,161 M
  • EBIT $ 2,163 M
  • EBITDA $ 2,689 M
  • 60-Month Beta -0.06
  • Price/Sales 2.58
  • Price/Cash Flow 9.44
  • Price/Book 1.55

Options Overview Details

View History
  • Implied Volatility 30.85% ( -1.05%)
  • Historical Volatility 23.32%
  • IV Percentile 59%
  • IV Rank 36.08%
  • IV High 47.65% on 07/25/24
  • IV Low 21.36% on 09/10/24
  • Put/Call Vol Ratio 0.37
  • Today's Volume 4,151
  • Volume Avg (30-Day) 3,667
  • Put/Call OI Ratio 0.70
  • Today's Open Interest 51,921
  • Open Int (30-Day) 50,191

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 3.39
  • Number of Estimates 22
  • High Estimate 3.77
  • Low Estimate 2.61
  • Prior Year 2.95
  • Growth Rate Est. (year over year) +14.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
170.71 +1.65%
on 11/04/24
194.13 -10.62%
on 10/15/24
-12.16 (-6.55%)
since 10/04/24
3-Month
170.71 +1.65%
on 11/04/24
207.59 -16.41%
on 08/21/24
-32.14 (-15.63%)
since 08/02/24
52-Week
170.71 +1.65%
on 11/04/24
268.30 -35.32%
on 01/03/24
-75.98 (-30.45%)
since 11/03/23

Most Recent Stories

More News
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

BIIB : 173.52 (-0.16%)
Biogen (BIIB) Q3 2024 Earnings Call Transcript

BIIB earnings call for the period ending September 30, 2024.

BIIB : 173.52 (-0.16%)
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases

BIIB : 173.52 (-0.16%)
Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

BIIB : 173.52 (-0.16%)
Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025

BIIB : 173.52 (-0.16%)
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

BIIB : 173.52 (-0.16%)
Biogen's Q3 2024 Earnings: What to Expect

Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip.

XLV : 146.77 (-0.66%)
$SPX : 5,712.69 (-0.28%)
BIIB : 173.52 (-0.16%)
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference

BIIB : 173.52 (-0.16%)
The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

For Immediate ReleaseChicago, IL – October 24, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

NVO : 109.72 (-1.98%)
NVS : 110.52 (+1.07%)
REGN : 828.84 (-1.75%)
PFE : 27.76 (-1.17%)
BIIB : 173.52 (-0.16%)
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect

Amgen AMGN will report third-quarter 2024 results on Oct. 30, after market close. In the last reported quarter, the company beat earnings expectations by 0.81%.The Zacks Consensus Estimate for sales and...

REGN : 828.84 (-1.75%)
AMGN : 316.91 (-0.72%)
PFE : 27.76 (-1.17%)
BIIB : 173.52 (-0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 179.48
2nd Resistance Point 177.17
1st Resistance Point 175.34
Last Price 173.52
1st Support Level 171.20
2nd Support Level 168.89
3rd Support Level 167.06

See More

52-Week High 268.30
Fibonacci 61.8% 231.02
Fibonacci 50% 219.50
Fibonacci 38.2% 207.99
Last Price 173.52
52-Week Low 170.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar